JP7561632B2 - プロテアソーム活性増強化合物 - Google Patents

プロテアソーム活性増強化合物 Download PDF

Info

Publication number
JP7561632B2
JP7561632B2 JP2020573524A JP2020573524A JP7561632B2 JP 7561632 B2 JP7561632 B2 JP 7561632B2 JP 2020573524 A JP2020573524 A JP 2020573524A JP 2020573524 A JP2020573524 A JP 2020573524A JP 7561632 B2 JP7561632 B2 JP 7561632B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529792A5 (https=
JP2021529792A (ja
JPWO2020006296A5 (https=
Inventor
マシュー カレン，
セシリア エム． バストス，
ダニエル パークス，
ベニート ムノズ，
Original Assignee
キネタ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キネタ， インコーポレイテッド filed Critical キネタ， インコーポレイテッド
Publication of JP2021529792A publication Critical patent/JP2021529792A/ja
Publication of JP2021529792A5 publication Critical patent/JP2021529792A5/ja
Publication of JPWO2020006296A5 publication Critical patent/JPWO2020006296A5/ja
Priority to JP2024094936A priority Critical patent/JP2024138260A/ja
Application granted granted Critical
Publication of JP7561632B2 publication Critical patent/JP7561632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020573524A 2018-06-27 2019-06-27 プロテアソーム活性増強化合物 Active JP7561632B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094936A JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690563P 2018-06-27 2018-06-27
US201862690565P 2018-06-27 2018-06-27
US62/690,565 2018-06-27
US62/690,563 2018-06-27
PCT/US2019/039600 WO2020006296A1 (en) 2018-06-27 2019-06-27 Proteasome activity enhancing compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094936A Division JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Publications (4)

Publication Number Publication Date
JP2021529792A JP2021529792A (ja) 2021-11-04
JP2021529792A5 JP2021529792A5 (https=) 2022-06-29
JPWO2020006296A5 JPWO2020006296A5 (https=) 2022-06-29
JP7561632B2 true JP7561632B2 (ja) 2024-10-04

Family

ID=67439356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573524A Active JP7561632B2 (ja) 2018-06-27 2019-06-27 プロテアソーム活性増強化合物
JP2024094936A Withdrawn JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094936A Withdrawn JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Country Status (17)

Country Link
US (2) US11560385B2 (https=)
EP (1) EP3814338A1 (https=)
JP (2) JP7561632B2 (https=)
KR (1) KR20210024588A (https=)
CN (1) CN112585132B (https=)
AU (1) AU2019295765B2 (https=)
BR (2) BR112020026580A2 (https=)
CA (1) CA3103954A1 (https=)
CL (1) CL2020003380A1 (https=)
CR (1) CR20200652A (https=)
IL (1) IL279698A (https=)
MA (1) MA53014A (https=)
MX (1) MX2020014082A (https=)
PE (1) PE20211804A1 (https=)
PH (1) PH12020552261A1 (https=)
SG (1) SG11202013026WA (https=)
WO (1) WO2020006296A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
CN111423353B (zh) * 2020-04-29 2022-03-22 湖北省生物农药工程研究中心 多取代n-芳基吡咯类化合物及其制备方法
CN112142642B (zh) * 2020-10-15 2022-03-04 华侨大学 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法
WO2023107597A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Bicyclic heteroaromatic amide compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514362A (ja) 2011-05-12 2014-06-19 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1142508A (en) 1966-04-27 1969-02-12 Whitefin Holding Sa Pyrrole derivatives
GB1154744A (en) 1966-05-17 1969-06-11 Whitefin Holding Sa Disubstituted Aminoethanols
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
CZ20002669A3 (cs) 1998-01-23 2001-11-14 National Jewish Medical And Research Center Pouľití proteinů tepelného ąoku nebo molekuly nukleové kyseliny, která jej kóduje, přípravek tyto látky obsahující, způsob výběru léčby přecitlivělosti nebo nedostatečnosti průchodu dýchacích cest
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
US20060148767A1 (en) 2001-12-06 2006-07-06 George Cioca Use of acyl salicylates as heat shock inducers
EP1682504B1 (en) 2003-11-12 2012-12-26 Amicus Therapeutics Inc. Hydroxy piperidine derivatives to treat gaucher disease
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101541172A (zh) 2005-06-08 2009-09-23 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
US20070207992A1 (en) 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
WO2007131034A1 (en) 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
PT1860101E (pt) 2006-05-24 2011-07-12 Amicus Therapeutics Inc Sal de tartrato da isofagomina e métodos de uso
JP5303458B2 (ja) 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
MX336731B (es) * 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
US9849135B2 (en) * 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514362A (ja) 2011-05-12 2014-06-19 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RN 1025028-84-5 ，Database REGISTRY [online]，2008年06月03日，[検索日：2023年5月24日] Retrieved from: STN

Also Published As

Publication number Publication date
US20230183256A1 (en) 2023-06-15
WO2020006296A1 (en) 2020-01-02
US20210115057A1 (en) 2021-04-22
US12319698B2 (en) 2025-06-03
EP3814338A1 (en) 2021-05-05
BR112020026580A2 (pt) 2021-03-23
SG11202013026WA (en) 2021-01-28
KR20210024588A (ko) 2021-03-05
PE20211804A1 (es) 2021-09-14
MA53014A (fr) 2021-05-05
BR122023023216A2 (pt) 2024-02-20
PH12020552261A1 (en) 2021-08-02
CN112585132A (zh) 2021-03-30
IL279698A (en) 2021-03-01
JP2021529792A (ja) 2021-11-04
US11560385B2 (en) 2023-01-24
CL2020003380A1 (es) 2021-05-14
CN112585132B (zh) 2025-02-28
CA3103954A1 (en) 2020-01-02
MX2020014082A (es) 2021-04-13
AU2019295765B2 (en) 2024-08-29
JP2024138260A (ja) 2024-10-08
AU2019295765A1 (en) 2021-01-21
CR20200652A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
JP7561632B2 (ja) プロテアソーム活性増強化合物
ES2641478T3 (es) Derivados de 3-acetilamino-1-(fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino)benceno para el tratamiento de trastornos hiperproliferativos
JP6208122B2 (ja) プロテオスタシス調節因子
JP6657413B2 (ja) Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
JP2021510818A5 (https=)
US11981682B2 (en) Substituted cyclopenta[c]pyrroles as ABHD6 antagonists
US20250059189A1 (en) Pyridine derivatives and their use as sodium channel activators
JP2024112835A (ja) プロテアソーム活性増強化合物
CA3087807A1 (en) Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
HK40050827A (en) Proteasome activity enhancing compounds
RU2857204C2 (ru) Антагонист abhd6
HK40050827B (zh) 蛋白酶体活性增强化合物
TW202416956A (zh) 含有abhd6拮抗劑之醫藥組合物
HK40116639A (zh) 用於治疗弗里德希共济失调的化合物和方法
HK40098185A (zh) 作为组蛋白脱乙酰酶6抑制剂的1，3，4-恶二唑硫羰基化合物及包含该化合物的药物组合物
HK40049558A (en) Proteasome activity enhancing compounds
EP2167508A1 (en) Compounds for treating duchenne muscular dystrophy
BR112013017987A2 (pt) derivados heterocíclicos e seu uso no tratamento de distúrbios neurológicos
NZ612990B2 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
CN108264518A (zh) 苯并三环类衍生物、其制备方法与用途
NZ612990A (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220621

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240924

R150 Certificate of patent or registration of utility model

Ref document number: 7561632

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150